|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
8.170 +0.450 (+5.829%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 17,574,778 | 10.711% | 28,866,159 | 26,199,409 | 28,780,412 | 26,861,356 |
| Cost of Sales | (3,081,084) | 8.307% | (5,336,218) | (4,989,877) | (5,795,510) | (5,332,095) |
| Gross Profit | 14,493,694 | 11.236% | 23,529,941 | 21,209,532 | 22,984,902 | 21,529,261 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (4,823) | -94.817% | (118,299) | (525,710) | (152,976) | 13,630,790 | |
| Profit / (Loss) before Taxation | 5,966,963 | 65.106% | 5,277,468 | 5,409,906 | 5,778,604 | 18,572,673 | |
| Taxation | (981,324) | 59.801% | (492,918) | (797,267) | (775,986) | (1,957,880) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | 1,580,132 | 484,759 | -- | -- | |
| Non-controlling Interests | (1,597,048) | 0.473% | (2,864,848) | (2,765,459) | (2,459,048) | (2,006,381) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,388,591 | 12.311% | 3,499,834 | 2,331,939 | 2,543,570 | 14,608,412 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (250,372) | 257.118% | (204,447) | 116,902 | 237,617 | 146,560 |
| Depreciation & Amortisation | 575,692 | 12.830% | 1,321,181 | 1,036,695 | 1,046,984 | 992,556 |
| Directors' Emoluments | -- | -- | 205,314 | 203,407 | 227,139 | 176,656 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 18.820 | 14.826% | 19.130 | 12.590 | 13.660 | 77.830 |
| DPS (cts) | 4.562 | -- | 6.530 | 4.534 | 10.505 | 6.488 |
| Dividend Payout Ratio (%) | 24.242% | -- | 34.134% | 36.015% | 76.904% | 8.336% |
| Cash flow per share ($) | -- | -- | 0.362 | 0.327 | 0.336 | 0.286 |
| NBV per share ($) | 1.779 | -- | 1.701 | 1.621 | 1.581 | 1.608 |
| Remarks: | Real time quote last updated: 22/08/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,388,591 |
| %Change | 12.311% |
| EPS / (LPS) | RMB 0.188 |
| NBV Per Share (¥) | RMB 1.779 |